Hyperventilation Versus Exercise Testing Sensitivity in Exercise Induced Asthma

NCT ID: NCT03063424

Last Updated: 2019-06-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2019-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The diagnosis of exercise-induced bronchospasm (EIB) is difficult. The metacholine challenge test is not enough specific for the diagnosis of EIB. The exercise challenge test on a cycle ergometer is often use to diagnose this condition. This test has very high specificity, but not enough sensibility because the ventilation achieved during this test is often not big enough to induce a bronchospasm, especially in trained athletes. Eucapnic voluntary hyperventilation (EVH) is the recommended test of the Olympic National committee to establish the diagnosis of EIB, but there are no study comparing the sensibility and specificity of the cycle ergometer challenge test and the isocapnic hyperventilation in an establish population of asthmatics. The investigators assume that the sensitivity and specificity of EVH are higher than those of the cycle ergometer for the diagnosis of EIB in a population of asthmatics with symptoms suggestive of bronchospasm on exertion. In a population of asthmatics with exercise symptoms, what is the sensitivity and specificity of EVH and exercise challenge on a cycle ergometer for the diagnosis of EIB?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Exercise Induced Bronchospasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy subjects

Group Type OTHER

Eucapnic voluntary hyperventilation

Intervention Type DIAGNOSTIC_TEST

Exercise challenge on a cycle ergometer

Intervention Type DIAGNOSTIC_TEST

Asthmatics with EIB

Group Type OTHER

Eucapnic voluntary hyperventilation

Intervention Type DIAGNOSTIC_TEST

Exercise challenge on a cycle ergometer

Intervention Type DIAGNOSTIC_TEST

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Eucapnic voluntary hyperventilation

Intervention Type DIAGNOSTIC_TEST

Exercise challenge on a cycle ergometer

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject must have a diagnosis of asthma according to 2010 Canadian Thoracic Society consensus criteria since more then one year.
* The subject should have an average expiratory volume per second (FEV1) ≥ 80% of the predicted value (post bronchodilatation) at the time of the initial visit.
* The subject must have had a positive methacholine test at the first visit of the study demonstrating the presence of bronchial hyperreactivity.
* The subject must have asthma control as defined by 2010 Canadian Thoracic Society consensus, with the obvious exception of limitations related to physical activity.
* The subject must have at the questionnaire significant symptoms of exercise-induced bronchospasm for more than 6 months.


* The subject should not have a positive history of eczema, urticaria or allergic rhinitis for life.
* The subject should have a FEV1 ≥ 80% of the predicted value and an FEV1 / FVC (Forced vital capacity) ratio of ≥70% at the time of the initial visit.
* The subject should have a negative methacholine test at the first visit of the study.
* The subject should not exhibit symptoms considered clinically compatible with EIB diagnosis.

Exclusion Criteria

* Pregnant or breast-feeding women.
* The subject should not suffer from clinically significant concomitant diseases that may compromise the course of the study.
* The subject should not have taken per os or intravenously steroids in the 8 weeks prior to the study.
* The subject should not have experienced significant symptoms of respiratory tract infection (viral or bacterial) in the 8 weeks prior to the study.
* The subject must not have participated in another study during the month preceding the date of enrollment of this study.
* The subject should not have smoked within the last 6 months.


* The subject doesn't show up for all 3 visits or doesn't complete all required exams.
* The subject develops a respiratory tract infection, an acute exacerbation of his asthma or any other conditions that compromise his participation in the required examinations.
* The subject has a pre-test FEV1 of less than 80%.
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Université de Sherbrooke

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Brian Grondin-Beaudoin

Clinical Professor, Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre Larivée

Role: PRINCIPAL_INVESTIGATOR

Université de Sherbrooke

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Université de Sherbrooke

Sherbrooke, Quebec, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Brian Grondin-Beaudoin

Role: CONTACT

819-346-1110 ext. 14252

Katia Carle-Talbot

Role: CONTACT

514-592-1113 ext. pag 0477

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Katia Carle-Talbot, MD, resident

Role: primary

514-592-1113 ext. pag 3388

Brian Grondin-Beaudoin, MD

Role: backup

819-346-1110 ext. 14252

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10-074

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Impact of NaHCO3- on Exercise Hyperpnea
NCT03057535 COMPLETED EARLY_PHASE1